17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
CAS: 16590-41-3
Ref. 3D-FC46032
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire | ||
250mg | To inquire |
Product Information
- Naltrexone
- (1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-on
- (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one
- (5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
- (5alpha)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one
- 1-N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynormorphinone
- 16590-41-3
- Depotrex
- En 1639
- En 1639A
- See more synonyms
- Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-
- Morphinan-6-one, 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-
- N-Cyclopropylmethylnoroxymorphone
- Naltrel
- Naltrexon
- Naltrexona
- Nemexin
- ReVia
- Trexonil
- Um 792
- Vivitrex
- Vivitrol
Naltrexone is a drug that is used in the pharmacological treatment of bowel disease. It is an opioid antagonist and has been shown to inhibit binding of opioid receptor agonists in vitro. Naltrexone blocks the effect of opioids by binding to the same receptors, blocking their ability to produce a response. The efficacy of naltrexone for treating bowel disease has been demonstrated in clinical trials with an intention-to-treat population and using the Mayo Clinic activity index.
Chemical properties
Technical inquiry about: 3D-FC46032 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.